238,193 Shares in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Acquired by Boxer Capital Management LLC

Boxer Capital Management LLC bought a new position in shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 238,193 shares of the company's stock, valued at approximately $953,000. Boxer Capital Management LLC owned 0.63% of Orchestra BioMed as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in OBIO. SG Americas Securities LLC boosted its holdings in shares of Orchestra BioMed by 26.0% during the 4th quarter. SG Americas Securities LLC now owns 12,785 shares of the company's stock worth $51,000 after buying an additional 2,642 shares during the period. Wells Fargo & Company MN boosted its holdings in Orchestra BioMed by 43.6% during the fourth quarter. Wells Fargo & Company MN now owns 13,156 shares of the company's stock valued at $53,000 after acquiring an additional 3,992 shares during the period. The Manufacturers Life Insurance Company grew its position in shares of Orchestra BioMed by 11.1% in the fourth quarter. The Manufacturers Life Insurance Company now owns 37,009 shares of the company's stock valued at $148,000 after purchasing an additional 3,704 shares during the last quarter. Barclays PLC increased its stake in shares of Orchestra BioMed by 18.9% in the fourth quarter. Barclays PLC now owns 37,786 shares of the company's stock worth $152,000 after purchasing an additional 6,001 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in shares of Orchestra BioMed by 354.5% during the 4th quarter. JPMorgan Chase & Co. now owns 49,405 shares of the company's stock worth $198,000 after purchasing an additional 38,535 shares during the last quarter. Institutional investors and hedge funds own 53.55% of the company's stock.

Orchestra BioMed Stock Up 0.6 %

Shares of OBIO stock traded up $0.02 during trading on Wednesday, reaching $2.44. 101,998 shares of the company's stock were exchanged, compared to its average volume of 156,827. The firm's fifty day moving average price is $3.46 and its 200-day moving average price is $4.73. The stock has a market capitalization of $93.29 million, a PE ratio of -1.51 and a beta of 0.67. Orchestra BioMed Holdings, Inc. has a twelve month low of $2.38 and a twelve month high of $8.87.

Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last announced its earnings results on Monday, March 31st. The company reported ($0.43) EPS for the quarter, hitting the consensus estimate of ($0.43). Orchestra BioMed had a negative net margin of 2,179.33% and a negative return on equity of 107.04%. The company had revenue of $0.25 million for the quarter, compared to analysts' expectations of $0.79 million. As a group, analysts anticipate that Orchestra BioMed Holdings, Inc. will post -1.66 EPS for the current fiscal year.

Analyst Ratings Changes

OBIO has been the topic of a number of research analyst reports. BTIG Research assumed coverage on Orchestra BioMed in a report on Thursday, March 20th. They issued a "buy" rating and a $12.00 target price on the stock. Chardan Capital reaffirmed a "buy" rating and issued a $20.00 target price on shares of Orchestra BioMed in a research report on Tuesday, April 22nd. Barclays reduced their price objective on shares of Orchestra BioMed from $16.00 to $12.00 and set an "overweight" rating for the company in a report on Monday. B. Riley upgraded shares of Orchestra BioMed to a "strong-buy" rating in a research report on Thursday, April 3rd. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Orchestra BioMed in a report on Wednesday, April 23rd. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Orchestra BioMed presently has an average rating of "Buy" and a consensus price target of $14.20.

Orchestra BioMed Company Profile

Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.